Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (101-110 of 492) with videos related to

Pageof 50
Sort By:
Current Drug Targets|July 23, 2011
HGF/c-MET targeted therapeutics: novel strategies for cancer medicineTimothy A Yap, Shahneen K Sandhu, Salma M Alam, et al.
The Oncologist|September 28, 2011
Revisiting the role of antiandrogen strategies in ovarian cancerDionysis Papadatos-Pastos, Konstantin J Dedes, Johann S de Bono, et al.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
The Journal of Pathology|October 11, 2013
Molecular pathology and prostate cancer therapeutics: from biology to bedsideDaniel Nava Rodrigues, Lisa M Butler, David Lorente Estelles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
Targeting the PI3K/AKT pathway for the treatment of prostate cancerDebashis Sarker, Alison H M Reid, Timothy A Yap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Reply to A. Addeo and A. BahlHoward I Scher, Glenn Heller, Arturo Molina, et al.
JCO Precision Oncology|January 5, 2024
Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future ProspectsZhulin Yin, Adrian P Mander, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Circulating tumor cells: a multifunctional biomarkerTimothy A Yap, David Lorente, Aurelius Omlin, et al.
The Lancet. Oncology|June 13, 2015
Sequencing of agents in castration-resistant prostate cancerDavid Lorente, Joaquin Mateo, Raquel Perez-Lopez, et al.
Molecular Cell|June 20, 2015
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor FunctionFelix Y Feng, Johann S de Bono, Mark A Rubin, et al.
Pageof 50

Showing results (101-110 of 492) with videos related to

Sort By:
Pageof 50
Current Drug Targets|July 23, 2011
HGF/c-MET targeted therapeutics: novel strategies for cancer medicineTimothy A Yap, Shahneen K Sandhu, Salma M Alam, et al.
The Oncologist|September 28, 2011
Revisiting the role of antiandrogen strategies in ovarian cancerDionysis Papadatos-Pastos, Konstantin J Dedes, Johann S de Bono, et al.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
The Journal of Pathology|October 11, 2013
Molecular pathology and prostate cancer therapeutics: from biology to bedsideDaniel Nava Rodrigues, Lisa M Butler, David Lorente Estelles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
Targeting the PI3K/AKT pathway for the treatment of prostate cancerDebashis Sarker, Alison H M Reid, Timothy A Yap, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Reply to A. Addeo and A. BahlHoward I Scher, Glenn Heller, Arturo Molina, et al.
JCO Precision Oncology|January 5, 2024
Handling Incomplete or Late-Onset Toxicities in Early-Phase Dose-Finding Clinical Trials: Current Practice and Future ProspectsZhulin Yin, Adrian P Mander, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Circulating tumor cells: a multifunctional biomarkerTimothy A Yap, David Lorente, Aurelius Omlin, et al.
The Lancet. Oncology|June 13, 2015
Sequencing of agents in castration-resistant prostate cancerDavid Lorente, Joaquin Mateo, Raquel Perez-Lopez, et al.
Molecular Cell|June 20, 2015
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor FunctionFelix Y Feng, Johann S de Bono, Mark A Rubin, et al.
Pageof 50